Table 2

Characteristics, management and outcomes of rheumatic irAEs

PatientRheumatic irAETime to onset (weeks)bDMARD/ tsDMARDPrevious treatment for irAEbDMARD/ tsDMARD duration (weeks)irAE outcomeCancer outcomeGC tapering (mg/day)
1RA-like131EtanerceptGC, MTX86 (ongoing)ResolutionRemission0
2RA-like22InfliximabGC, MTX8ResolutionProgression0
3RA-like14TocilizumabGC, MTX8Partial improvementProgression20
4RA-like16TocilizumabGC34Partial improvementProgression*10
5PMR-like3TocilizumabGC53 (ongoing)Partial improvementStable2
6RA-like24TocilizumabGC, MTX69 (ongoing)ResolutionRemission0
7RA-like2TocilizumabGC, MTX8ResolutionProgression*10
8PMR-like48TocilizumabGC, MTX48 (ongoing)ResolutionRemission0
9PsA-like8TocilizumabNSAIDs, GC, MTX43 (ongoing)Partial improvementProgression2.5
10RA-like331/Tocilizumab 2/BaricitinibGC, MTX1/6
2/78 (ongoing)
1/No improvement 2/ResolutionProgression0
11PsA-like34UstekinumabGC60 (ongoing)Partial improvementStable5
12RA-like20AdalimumabGC, MTX8 (ongoing)ResolutionRemission0
13RA-like26AdalimumabGC34Partial improvementProgression5
14RA-like16TocilizumabGC, MTX8No improvementRemission5
15RA-like64TocilizumabGC, MTX17Partial improvementProgression5
16RA-like156TocilizumabGC8 (ongoing)Partial improvementStable5
17RA-like22SarilumabNSAIDs, GC, MTX12 (ongoing)Partial improvementPartial response7.5
18RA flare0TocilizumabGC22Partial improvementProgression*15
19RA-like69AnakinraColchicine1No improvementStable0
20RA flare1EtanerceptGC8No improvementProgression*80
  • *Death.

  • bDMARD, biologic disease-modifying antirheumatic drug; GC, glucocorticoids; irAE, immune-related adverse event; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PMR, polymyalgia rheumatica; PsA, psoriatic arthritis; RA, rheumatoid arthritis; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.